Pablo Legorreta has been our Chief Executive Officer and chairman since inception. Previously, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a co-founder of Pharmakon Advisors, a leading provider of debt capital to the biopharmaceutical industry. Mr. Legorreta serves on several boards including the New York Academy of Sciences, Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur), Open Medical Institute, Park Avenue Armory, Epizyme, Inc., ITB-Med Pharmaceuticals, Nefro Health and ProKidney, LLC. Mr. Legorreta was the founder and is currently Honorary Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and Provided by Tagnifi.
Pablo is the founder, CEO and Chairman of Royalty Pharma plc. Since its founding in 1996, Royalty Pharma has been the pioneer and market leader in royalty funding of life science innovation. The company’s collaborations span the entire research and development ecosystem, from academic institutions, research hospitals and not-for-profits to small- and mid-cap biotechnology companies and global pharmaceutical companies. To date, Royalty Pharma has deployed more than $20 billion of capital to advance innovation in the biopharmaceutical industry.
Pablo is a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. He is also a co-founder of ProKidney, LLC, a biotech company developing pioneering therapies that have the potential to change the lives of people with chronic kidney disease.
Pablo is also the founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities.
Pablo serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, the Hospital for Special Surgery, Pasteur Foundation (US), Open Medical Institute and Park Avenue Armory.
Prior to founding Royalty Pharma, Pablo was an investment banker at Lazard Frères in Paris and New York.
What is Pablo G. Legorreta's net worth?
The estimated net worth of Pablo G. Legorreta is at least $563.64 million as of June 13th, 2024. Mr. Legorreta owns 22,617,909 shares of Royalty Pharma stock worth more than $563,638,292 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Legorreta may own. Learn More about Pablo G. Legorreta's net worth.
How old is Pablo G. Legorreta?
Mr. Legorreta is currently 60 years old. There are 5 older executives and no younger executives at Royalty Pharma. The oldest executive at Royalty Pharma is Mr. George Wingate Lloyd, Executive VP of Investments & Chief Legal Officer, who is 64 years old. Learn More on Pablo G. Legorreta's age.
How do I contact Pablo G. Legorreta?
Has Pablo G. Legorreta been buying or selling shares of Royalty Pharma?
Pablo G. Legorreta has not been actively trading shares of Royalty Pharma in the last ninety days. Most recently, on Wednesday, June 28th, Pablo G. Legorreta bought 130,000 shares of Royalty Pharma stock. The stock was acquired at an average cost of $29.51 per share, with a total value of $3,836,300.00. Following the completion of the transaction, the chief executive officer now directly owns 600,000 shares of the company's stock, valued at $17,706,000. Learn More on Pablo G. Legorreta's trading history.
Who are Royalty Pharma's active insiders?
Are insiders buying or selling shares of Royalty Pharma?
In the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 312,631 shares worth more than $8,860,323.39. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.9% of the company.
Learn More about insider trades at Royalty Pharma. Information on this page was last updated on 1/4/2024.
